Last reviewed · How we verify
nsclc pd l1
Approved treatments
Clinical guidelines
- FDA label — 1L
As a single agent for the first-line treatment of adult patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. - FDA label — 1L
In combination with platinum and FU for the first-line treatment of adult patients with metastatic or with unresectable, recurrent HNSCC. As a single agent for the first-line treatment of adult patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- nsclc pd l1 patent landscape — cliff calendar, originator estates, attackable patents
- nsclc pd l1 treatment landscape brief
- nsclc pd l1 treatment updates RSS
Frequently asked questions about nsclc pd l1
What are the treatment guidelines for nsclc pd l1?
FDA label publishes guidelines for nsclc pd l1. 2 guideline references tracked.
Related
- Treatment landscape: nsclc pd l1 patent cliff · nsclc pd l1 CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing